“Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses. I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long-term value to all of our stakeholders.”


*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Note: values may have been rounded

2nd Quarter 2021 Results

<table>
<thead>
<tr>
<th>2nd Quarter 2021 Sales</th>
<th>Adjusted Diluted Earnings Per Share*</th>
</tr>
</thead>
<tbody>
<tr>
<td>$23.3B</td>
<td>$2.48</td>
</tr>
<tr>
<td>27.1%</td>
<td>48.5%</td>
</tr>
</tbody>
</table>

Diluted Earnings Per Share

<table>
<thead>
<tr>
<th></th>
<th>Increased</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.35</td>
<td>72.8%</td>
</tr>
</tbody>
</table>

Worldwide Consumer Health Sales

Consumer Health worldwide reported sales increased 13.3% or 9.2% operationally. Primary operational drivers:

- Aveeno
- Neutrogena
- Listerine
- Band-Aid

Worldwide Pharmaceutical Sales

Pharmaceutical worldwide reported sales increased 17.2% or 13.6% operationally. Primary operational drivers:

- Stelara
- Darzalex
- Imbruvica
- Trevfya
- Opsumt

Worldwide Medical Devices Sales

Medical Devices worldwide reported sales increased 62.7% or 57.2% operationally. Primary operational drivers:

- Contact Lenses
- Wound Closure
- Biosurgery
- Electrophysiology
- Tissue

Note: values may have been rounded

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on July 21, 2021, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.